Reply to 'Concern on quality-of-life analysis in the OPTIMAL study' by Couraud et al

Ann Oncol. 2013 Aug;24(8):2197-8. doi: 10.1093/annonc/mdt259.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • ErbB Receptors / genetics*
  • Female
  • Humans
  • Male
  • Mutation / genetics*
  • Quality of Life*

Substances

  • ErbB Receptors